Prima BioMed (NASDAQ:IMMP) Stock Crosses Below 50-Day Moving Average – Here’s Why

Prima BioMed Ltd (NASDAQ:IMMP)’s share price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.44 and traded as low as $0.37. Prima BioMed shares last traded at $0.3766, with a volume of 581,594 shares.

Prima BioMed News Roundup

Here are the key news stories impacting Prima BioMed this week:

• Positive Sentiment: Immutep said it will present positive interim Phase I data for IMP761, its first-in-class LAG-3 agonist antibody, at the EULAR 2026 conference, which could support the long-term pipeline story. Article Title
• Neutral Sentiment: Several law firms, including Rosen, Robbins LLP, Schall, DJS, Pomerantz, Bernstein Liebhard, and others, issued investor alerts and deadline reminders tied to an existing securities class action involving IMMP purchasers from March 24, 2025 to March 12, 2026. Article Title
• Neutral Sentiment: The lawsuit filings allege Immutep misled investors about the viability and efficacy of a drug candidate, with a lead-plaintiff deadline set for July 6, 2026. Article Title
• Negative Sentiment: One lawsuit notice described the case as stemming from an alleged “83% stock collapse,” reinforcing concerns that the company faces meaningful legal and reputational overhang. Article Title

Analyst Upgrades and Downgrades

IMMP has been the subject of several analyst reports. Wall Street Zen raised shares of Prima BioMed to a “hold” rating in a report on Saturday, April 18th. Maxim Group cut shares of Prima BioMed from a “buy” rating to a “hold” rating in a research report on Friday, March 13th. Robert W. Baird cut shares of Prima BioMed from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $7.00 to $1.00 in a research report on Friday, March 13th. Finally, Citizens Jmp cut shares of Prima BioMed from an “outperform” rating to a “market perform” rating in a research report on Friday, March 13th. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $5.50.

Prima BioMed Trading Down 3.1%

The firm’s 50-day moving average price is $0.44 and its 200-day moving average price is $1.73.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC lifted its holdings in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent quarter. 2.32% of the stock is currently owned by institutional investors and hedge funds.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.